Speaker Profile
Ph.D., Vice President, Head of Science, Oncology, Labcorp
Biography
Taylor Jensen joined Sequenom in 2009 and was part of the team that developed and launched the first commercially available noninvasive prenatal test based on cell-free DNA in the U.S. Subsequently, Dr. Jensen was involved in numerous development efforts focused on the detection of genomic and epigenomic changes in cfDNA for use in prenatal and cancer diagnostics. Since the acquisition of Sequenom by LabCorp in 2016, his work has been primarily focused on biomarkers, precision medicine diagnostic assays, and product strategy with the overarching goal of utilizing these technologies to improve human health. He is a member of multiple professional societies including AACR and ASCO, has contributed to multiple awarded patents, and has authored or co-authored more than 35 publications in peer reviewed scientific journals. He holds a Ph.D. in Pharmacology and Toxicology from the University of Arizona and was a postdoctoral fellow at the Arizona Cancer Center.
Clinical Dx Showcase:
Labcorp
Through unparalleled diagnostics and drug development capabilities, Labcorp provides insights and accelerate innovations to improve health and improve lives.
Session Abstract – PMWC 2025 Silicon Valley
The PMWC 2025 Data Applications in Clinical Diagnostics Showcase will provide a 15-30 minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.
- Clinical Dx/Oncology (including Liquid Biopsy)
- Clinical Dx/Cardio Vascular
- Clinical Dx/Neurodegenerative
